4 RESULTS
COMMENT The findings of Ewers et al. provide a valuable advance for understanding how measurements of the biomarker CSF sTREM2 relate to the rate of disease progression around the early symptomatic stages of Alzheimer’s. What the data imply, as far as TREM2 and ...
COMMENT How about we just close the book on naproxen? NSAIDs is a broad class of drugs, and it hardly seems appropriate to castigate the whole lot of them based on INTREPAD and ADAPT. If one were to simply follow the strongest epidemiological signal, then testing ...
COMMENT While this study is interesting since it seeks to correlate midlife (rather than elderly) fitness with AD risk, it has two major limitations that caution against reading too much into these findings. In addition to the small sample size mentioned above by ...
COMMENT The paper by Lee et al. is a momentous step forward for understanding how TREM2 function governs AD-related pathology. Genetic approaches in humans and mice had collectively shown that partial or complete loss of TREM2 function enhanced Alzheimer's ...
